跳至主要内容
临床试验/NCT05095766
NCT05095766已完成不适用

Differentiation Between Radionecrosis and Tumor Recurrence for Post-stereotactic Radiosurgery Follow-up by Pharmacokinetic Analyses in Perfusion MRI and Positron Emission Tomography

Centre de recherche du Centre hospitalier universitaire de Sherbrooke1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2017年11月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Comparison of novel MRI method with current MRI exam method

研究概览

简要总结

During gamma scalpel treatment of brain tumors and metastases, a follow-up magnetic resonance imaging (MRI) scan is performed. The radiologist who reviews the MRI assesses whether there is an increase in signal at the tumor site. This increase potentially indicates that the treatment was not effective. However, in 25% of cases (one in four people), this signal enhancement is not due to ineffective treatment, but to inflammation (swelling/damage) and tissue death around the tumor. This is why when an increase in signal is detected, additional follow-up is essential. The standard additional follow-up has an accuracy of about 83%.

This is an observational study on patients with brain metastatis comparing MRI alone or combined to PET-FET to improve accuracy of diagnosis of metastasis recurrence.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female over 18 years of age;
  • Having undergone gamma knife radiosurgery for brain metastasis;
  • Presenting for a first MRI follow-up (Cohort C1);
  • Presence of one or more brain metastases with increased enhancement on follow-up MRI (Cohort C2.1 and C2.2); A participant recruited for Cohort C1 could be recruited for follow-up in Cohort C2.1 or C2.2 if the MRI result is ambiguous.

排除标准

  • Pregnancy or breastfeeding;
  • Other condition that may influence the imaging result;
  • Renal impairment (<30 mL/min/1.73 m2). This threshold is consistent with recent RAC recommendations; Note: For participants with intermediate renal clearance (30-60 mL/min/1.73 m2), the total gadobutrol dose injected is set at the manufacturer's recommended clinical dose. For patients with renal clearance greater than 60 mL/min/1.73 m2, a dose of 1.5x the normal dose is used. These dose values have been approved by Dr. Chénard and are consistent with the RAC recommendations.
  • Inability to maintain supine position for the required duration (variable, depending on the sequence);
  • Patients who have previously received full brain irradiation;
  • Patients who are claustrophobic and cannot tolerate insertion into the MRI scanner;

结局指标

主要结局

Comparison of novel MRI method with current MRI exam method

时间窗: Following MRI exam

In the context of differentiating radionecrosis and recurrence of metastasis: Is our new method better than the actual standard of care in Sherbrooke?

Comparison of DCE-MRI method with FET PET

时间窗: Following MRI exam

In the context of differentiating radionecrosis and recurrence of metastasis: is one better than the other? And Can DCE-MRI and FET PET be combined to differentiate between recurrence/radionecrosis?

次要结局

未报告次要终点

研究者

发起方
Centre de recherche du Centre hospitalier universitaire de Sherbrooke
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验